• Recruiting

NCT03777410: Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma

NCT03777410: Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma


mass accumulation rate


Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma


This study will collect bone marrow (BM) aspirate samples from patients with relapsed refractory multiple myeloma (RRMM) prior to the start of a new treatment regimen for the purposes of prospectively measuring single-cell mass accumulation rate (MAR) as a biomarker of patient response to that regimen.


Sponsor:

Travera LLC


Collaborators:

Dana-Farber Cancer Institute

Massachusetts General Hospital

Weill Medical College of Cornell University

Icahn School of Medicine at Mount Sinai

City of Hope Comprehensive Cancer Center

Emory University


Locations

United States, California

United States, Georgia

United States, Massachusetts

United States, New York

 

ClinicalTrials.gov Identifier: NCT03777410


Official Title: Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma

First Posted: December 17, 2018


Click here for details on ClinicalTrials.gov

 










Posts Archive